Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
31 stopped studies mapped to Basal Cell Carcinoma and descendants · 87% state a reason
Over the 31 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04155190 | A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently… | Phase 2 | terminated | Nov 7, 2019 | Sol-Gel Technologies, Ltd. | Terminated early due to low blinded event rate | Other (stated, no rule matched) |
| NCT05929664 | Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell… | Phase 2 | suspended | Jul 3, 2023 | Thomas Jefferson University | Investigational product is not currently available to the study site. | Other (stated, no rule matched) |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT03646188 | Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of… | Phase 1 | terminated | Aug 24, 2018 | SkinJect, Inc. | Application of arrays was inconsistent. | Other (stated, no rule matched) |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04099446 | A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer | — | withdrawn | Sep 23, 2019 | ProgenaBiome | Sponsor decision | Sponsor / business decision |
| NCT05110924 | RCT Treatment Versus Non Treatment of Low-risk BCCs in Elderly(BASINEL) | N/A | terminated | Nov 8, 2021 | University Hospital, Ghent | Low recruitment | Enrollment / accrual |
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | — | terminated | Dec 12, 2017 | Washington University School of Medicine | Subject recruitment was limited severely by the 2020-2023 COVID-19 pandemic, which led this study… | COVID-19 / pandemic |
| NCT04410874 | Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer(MUSIC-01) | Phase 1 / Phase 2 | terminated | Jun 1, 2020 | Ivan Litvinov | Inability to recruit patients/lack of funding | Enrollment / accrual |
| NCT04510727 | Optical Coherence Tomography Guided C&D | N/A | withdrawn | Aug 12, 2020 | University of Miami | device not available to initiate study. | Other (stated, no rule matched) |
| NCT04688749 | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage(DermaSense) | — | terminated | Dec 30, 2020 | Aristotle University Of Thessaloniki | Due to COVID-19 | COVID-19 / pandemic |
| NCT04093401 | The VIDYA Study-designed to Determine if Patients With a History of Basal Cell Carcinoma… | N/A | withdrawn | Sep 18, 2019 | University of Wisconsin, Madison | Resources | Other (stated, no rule matched) |
| NCT02699723 | Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer | Early Phase 1 | withdrawn | Mar 4, 2016 | Jean Yuh Tang | Logistics | Other (stated, no rule matched) |
| NCT02956889 | To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell…(virgilio) | Phase 2 | terminated | Nov 7, 2016 | Istituto Clinico Humanitas | low recruitment rate | Enrollment / accrual |
| NCT03420846 | Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping | N/A | terminated | Feb 5, 2018 | Michelson Diagnostics Ltd. | Funding exhausted. Sufficient data already collected. | Funding |
| NCT03321903 | EPR Tumor Oximetry With CE India Ink | — | terminated | Oct 26, 2017 | Philip Schaner | The research team is exploring device optimization | Other (stated, no rule matched) |
| NCT02067104 | Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention | Phase 2 | terminated | Feb 20, 2014 | University of Arizona | Low enrollment | Enrollment / accrual |
| NCT02303041 | Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic… | Phase 2 | terminated | Nov 27, 2014 | Anne Chang | Business Decision | Sponsor / business decision |
| NCT02750033 | Intraoperative Margin Assessment During Mohs Surgery | — | withdrawn | Apr 25, 2016 | Seton Healthcare Family | Protocol changed to meet IRB requirements for patient safety | Safety / toxicity |
| NCT01604252 | An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in… | — | terminated | May 23, 2012 | Genentech, Inc. | The study was terminated early by the Sponsor due to the high rate of discontinuation of subjects… | Safety / toxicity |
| NCT02321982 | Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery | N/A | withdrawn | Dec 22, 2014 | Dartmouth-Hitchcock Medical Center | Study topic is no longer being pursued by study team members | Other (stated, no rule matched) |
| NCT01898598 | A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell… | Phase 2 | terminated | Jul 12, 2013 | Hoffmann-La Roche | not stated | Not stated |
| NCT03070691 | Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway… | Phase 2 / Phase 3 | withdrawn | Mar 3, 2017 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01808950 | Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular… | Phase 1 / Phase 2 | terminated | Mar 11, 2013 | Spirig Pharma Ltd. | safety issues | Safety / toxicity |
| NCT02059252 | Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold | Phase 1 / Phase 2 | terminated | Feb 11, 2014 | Smart Matrix Limited | Mode of application to be reconsidered by Sponsor | Other (stated, no rule matched) |
| NCT01033019 | To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial… | Phase 2 | terminated | Dec 16, 2009 | Novartis Pharmaceuticals | The data from participants with sBCCs showed insufficient efficacy with current formulation and… | Efficacy / futility |
| NCT02507076 | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma… | N/A | withdrawn | Jul 23, 2015 | Albert Einstein College of Medicine | no enrollment | Enrollment / accrual |
| NCT00994240 | Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC | N/A | terminated | Oct 14, 2009 | University of Wisconsin, Madison | slow enrollment, lack of funding | Enrollment / accrual |
| NCT00025051 | Celecoxib in Preventing Skin Cancer | Phase 2 | withdrawn | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00049959 | Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple… | Phase 3 | terminated | Nov 19, 2002 | QLT Inc. | not stated | Not stated |
| NCT00515970 | Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas | N/A | suspended | Aug 14, 2007 | University Hospital Tuebingen | Problems with the electronic data collection program | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 21, 2026source: clinicaltrials